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Kaposi's sarcoma-associated herpesvirus (KSHV), also
called human herpesvirus-8 (HHV-8) is the causative
agent of Kaposi's sarcoma (KS), primary effusion lym-
phoma (PEL), and a form of multicentric Castleman's dis-
ease (MCD). Two of these tumors, KS and PEL, tend to
arise in areas of the body that are relatively hypoxic.
Exploring this phenomenon, our group has previously
found that KSHV in PEL tumor cell lines is activated to
lytic replication by hypoxia and that certain KSHV genes
are activated by hypoxia inducible factors (HIF-1 and HIF-
2) through functional hypoxia response elements (HRE)
(Davis et al., Blood, 2001, 15, 3244–50; Haque et al., J.
Virol., 2006, 80, 7037–51). KS tumor cells are thought to
be derived from endothelial cells or their precursors, and
in the current study, we have addressed the question of
whether KSHV was similarly activated to lytic replication
in KSHV-infected endothelial cells.
To investigate this, we infected primary dermal microvas-
cular endothelial cells (DMEC) derived from human fore-
skin with a recombinant KSHV (rKSHV.219) that was
engineered to contain red fluorescent protein (RFP) con-
trolled by the lytic PAN RNA promoter as a lytic marker
and green fluorescent protein under the control of human
elongation factor 1-α promoter as a latent marker (gift of
Dr. Jeff Vieira). Short-term (<24 hours) exposure of these
KSHV-infected DMEC to hypoxia (1% O2) resulted in an
initial increase in the expression of KSHV lytic genes
(including RTA and viral interleukin [IL]-6) and secretion
of KSHV into the supernatant. However, when the
infected DMEC were cultured in hypoxia for > 24 hours,
there was a subsequent downregulation of KSHV lytic
genes and of the production of virus despite continued
upregulation of HIF-2 in the cells. We hypothesized that
this late downregulation might be from production of one
or more cellular factors with KSHV-suppressive activity in
these cells upon exposure to hypoxia. We focused on IL-
1β, IL-6, IL-8, tumor necrosis factor alpha (TNFα) and vas-
cular endothelial growth factor (VEGF), as these are
known to be produced by hypoxic endothelial cells and to
be expressed by KSHV-infected cells in vitro and in KS
lesions. IL-6, IL-1β and VEGF had no effect on lytic repli-
cation and IL8 increased replication in the KSHV-infected
DMEC. However, TNFα blocked the expression of RTA,
vIL6, ORF45 and K5 proteins and suppressed production
of KSHV virions in the supernatant. Furthermore, when
the cells were treated with blocking antibodies directed
against human TNFα, KSHV lytic activation in the hypoxic
DMEC was partially restored. Interestingly, established
monolayers of KSHV-infected DMEC cells cultured in
hypoxia out-survived normoxic cells cultured in parallel;
this provided evidence that suppression of KSHV by TNFα
was not simply from cell killing. These results suggest that
production of TNFα by KSHV-infected endothelial cells
may limit activation of lytic KSHV replication by hypoxia
and that this effect may promote survival of KSHV-
infected cells under hypoxic conditions and contribute to
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